Search results
Results From The WOW.Com Content Network
Meridian Bioscience (NAS: VIVO) reported earnings on Jan. 25. ... The stock has a five-star rating (out of five) at Motley Fool CAPS, with 463 members out of 474 rating the stock outperform, and ...
A look at the shareholders of Meridian Bioscience, Inc. (NASDAQ:VIVO) can tell us which group is most powerful... Skip to main content. Sign in. Mail. 24/7 Help. For premium support please call ...
Meridian Bioscience (VIVO) delivered earnings and revenue surprises of 16.67% and -2.26%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, diagnostic test maker Meridian Bioscience (NAS: VIVO) has ...
Last quarter, Meridian Bioscience tallied revenue of $47.4 million. GAAP reported sales were 16% higher than the prior-year quarter's $41.1 million. Source: S&P Capital IQ.
While Meridian Bioscience, Inc. (NASDAQ:VIVO) shareholders are probably generally happy, the stock hasn't had...
Meridian Bioscience (NAS: VIVO) reported earnings on April 25. Here are the numbers you need to know. The 10-second takeaway For the quarter ended March 31 (Q2), Meridian Bioscience missed ...
For premium support please call: 800-290-4726 more ways to reach us